Enter inventor name

Gerhard Sauer

This inventor holds 58 USPTO granted patents, primarily in Ergoline Derivatives (CPC class 2603). Top assignee: Schering Aktiengesellschaft. Active years: 1976-2005.

USPTO Granted Patents = 58

% Patents Active = 94.8

Average Co-Inventor Count = 4.5

ph-index = 11

Forward Citations = 343(Granted Patents)

Forward Citations (Not Self Cited) = 307(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

58 out of 1,384

Schering Aktiengesellschaft

patents

Years Active: 1976-2005

Loading Chart...

Areas of Expertise:

Ergoline Derivatives

Estratrienes

Pharmaceutical Preparations

Neuroleptic Activities

Androgen-Dependent Diseases

Selective Estrogens

Diagnostic Agents

Medicinal Compounds

Long-Chain Estratrienes

Bicycloalkane Derivatives

Alkyl Steroids

Lysergic Acid Esters

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6958327 - 18 Norsteroids as selectively active estrogens (2005-10-25),

2. 6790842 - 11&bgr; LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11&bgr; LONG-CHAIN SUBSTITUTED ESTATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS (2004-09-14),

3. 6780855 - 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 11&bgr;-HALOGEN-7&agr;-SUBSTITUTED ESTRATRIENES AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS (2004-08-24),

4. 6767903 - New7&agr;, 17&agr;-bis-alkylated testosterone derivatives and their use in long-term therapy of androgen-dependent diseases (2004-07-27),

5. 6288051 - 7 &agr;-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7 &agr;(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents (2001-09-11),

6. 6271403 - 7&agr;-(xi-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7&agr;-(xi-aminoalkyl-estratrienes as well as their use for the production of pharmaceutical agents (2001-08-07),

7. 5986115 - 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, (1999-11-16),

8. 5866560 - 7.alpha.-(.xi.-aminoalkyl)-estratrienes, process for their production, (1999-02-02),

9. 5547958 - N-(8.alpha.-ergolinyl)-amides (1996-08-20),

10. 5411966 - 2, 13-disubstituted ergolines, their production and use in (1995-05-02),

11. 5401748 - 2,14-disubstituted ergolines, their production and use in pharmaceutical (1995-03-28),

12. 5219862 - 8 beta-substituted ergolines, process for their production and their use (1993-06-15),

13. 5212178 - 8.alpha.-acylamino ergolines and use as pharmaceutical agents (1993-05-18),

14. 5158957 - 2-substituted ergolines (1992-10-27),

15. 5037832 - 2-substituted ergolines (1991-08-06),

Sure. Here is the article about inventor Gerhard Sauer:

Title: Innovator Spotlight: Gerhard Sauer - Pioneering Advances in Pharmaceuticals

Introduction:

Gerhard Sauer, a prolific inventor based in Berlin, Germany, has made significant contributions to the pharmaceutical industry with his groundbreaking innovations. With an impressive portfolio of 58 patents, Sauer has been a driving force in developing novel therapeutic agents.

Latest Patents:

1. "18 Norsteroids as selectively active estrogens": Sauer's invention introduces novel 18-norsteroids with high affinity for estrogen receptors, showcasing preferential activity in bone health and potential therapeutic applications for estrogen deficiency-induced diseases.

2. "11β Long-Chain Substituted Estratrienes": This patent describes a compound with antiestrogenic properties, offering new possibilities for pharmaceutical agents development.

Career Highlights:

Sauer is associated with Schering Aktiengesellschaft, a leading pharmaceutical company known for its innovative research and development in the field of healthcare. His tenure at Schering Aktiengesellschaft has been marked by a series of successful patent filings and groundbreaking discoveries.

Collaborations:

Throughout his career, Sauer has collaborated closely with esteemed colleagues such as Gregor Haffer and Rudolf Wiechert. Together, they have pushed the boundaries of pharmaceutical research, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, Gerhard Sauer stands out as a visionary inventor whose pioneering work continues to shape the landscape of pharmaceuticals. His relentless pursuit of scientific excellence and commitment to advancing healthcare make him a truly inspirational figure in the world of inventions and innovations.

If you need any more information or have any specific queries about Gerhard Sauer or any other inventor, feel free to ask!

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to [email protected]